

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

LETTER TO THE EDITOR

Can placebo challenge test (inducing a “nocebo effect”) be a suitable model to assess stress-induced bronchial obstruction? Suggestions from the multidisciplinary Working Groups “Stress-Asthma”^{*} and “AAITO Regione Campania”[†]

G. Liccardi ^{1*}†, L. Calzetta ^{1,2*}, M. Milanese ^{3*}, MB Bilò ^{4*}, MV Liccardi ^{5*}, I. Barordini ^{6*}, D. Gargano ^{7†}, M. Lo Schiavo ^{8†}, F. Madonna ^{9†}, MC. Montera ^{8†}, A. Papa ^{10†}, A. Pedicini ^{11†}, F. Habetswallner ^{12*}, A. Giordano ^{13†} and P. Rogliani ^{1,2*}

¹ Postgraduate School of Respiratory Medicine. Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy

² Department of Experimental Medicine, Unit of Respiratory Medicine. University of Rome "Tor Vergata", Rome, Italy

³ Division of Pulmonology, S. Corona Hospital, Pietra Ligure, Italy.

⁴ Allergy Unit, Department of Internal Medicine, University Hospital Ospedali Riuniti - Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.

⁵ Psychologist

⁶ Psychologist, Department of Biomedical Science, Humanitas University, Milan, Italy

⁷ Allergy Unit. High Speciality “San Giuseppe Moscati” Hospital, Avellino

⁸ Allergy and Clinical Immunology. “G. Fucito” Hospital and University Hospital, Salerno

⁹ Allergy Unit. ASL (Sanitary District n°12), Caserta

¹⁰ ASL (Sanitary District), Avellino

¹¹ Unit of Allergology. Division of Internal Medicine, “Fatebenefratelli” Hospital, Benevento

¹² Division of Neurophysiology, “A.Cardarelli” Hospital, Naples, Italy

¹³ Postgraduate School of Internal Medicine, University of Salerno, Italy

Word count: 1079

Short title: “Nocebo effect” and induction/aggravating bronchospasm in asthmatics.

49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96

Key words: adverse drug reaction, anxiety, bronchial asthma, bronchial obstruction, cholinergic tone, depression, increased cholinergic tone, hypersensitivity, nocebo effect, placebo challenge

Summary statement: Placebo challenge could be a useful model to study stress-induced bronchial obstruction in asthmatics suffering from psychological stress and suspected adverse drug reaction. Such obstruction should be a likely effect of stress-induced cholinergic hyper-tone.

Authorship: All authors contributed equally in the writing and revision of the manuscript.

Conflict of interest and financial resources. All authors declare that they have no conflict of interest and that the study has been carried out without any financial support.

Corresponding author

Gennaro Liccardi, MD

-Postgraduate School of Respiratory Medicine. Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy

Phone : +39 081 5780554; E-mail: gennaro.liccardi51@gmail.com

To the Editor

We read with interest the excellent article of Elizi et al. (1) reporting that female sex, older age and low level of education combined with a depressive tendency seem to be potential risk factors for “nocebo effect” appearing during oral challenge test in patients with drug adverse reactions (ADR).

They demonstrated that 10% of the examined patients reported respiratory symptoms (dyspnea and perception of laryngeal obstruction) as a consequence of the “nocebo effect” and this percentage was quite similar to that found in our previous Italian multicenter study (2). However, since the aim of study was a psychological assessment of these patients, they did not provide comments concerning the association between nocebo effect and respiratory symptoms in patients with ADR.

In other words, are reported respiratory symptoms (in asthmatics with real or “presumed” ADR) the consequence of a real bronchial obstruction, a condition associated to stress or both? It has been also demonstrated that inducible laryngeal obstruction, which is an induced and inappropriate narrowing of the larynx leading to symptomatic upper airway obstruction, can coexist with asthma (3). In fact, in this study, 42% of patients had objective evidence of both conditions, and symptoms possibly attributable to laryngeal obstruction are common (as “nocebo effect”) following placebo administration (3).

Based on these premises, we would like to discuss the possibility to use placebo administration as “drug provocation test” and inducing a “nocebo effect”, as a potential model to study the role of stress in triggering (or aggravating) bronchial obstruction in asthmatics (with a real or “presumed” ADR).

We have previously shown that about 63% of asthmatic patients reported the usual appearance of at least one non respiratory symptom (n-RS) before an asthma attack (4). Anxiety, and to a lesser extent depression represented the most common n-RSs in our study, suggesting that both disorders may have a possible role in the development and triggering of an asthma attack. Several studies have shown that psychological stress may enhance bronchial hyperreactivity through different mechanisms such as mast cell activation, mediator release, inflammation, and impairment of respiratory tolerance (5-7).

97 Another modality of inducing an increase in airway resistance in asthmatics (but also in healthy
98 individuals) is the use of visual unpleasant stimulations such as bloody or highly-arousal surgery films.
99 Ritz. et co-workers (8-10) reported a significant relationship between psycho-social stress and
100 stimulation of the cholinergic system, resulting in an increased airway resistance. The authors
101 demonstrated that unpleasant visual stimulations (i.e. bloody films) can rapidly induce (after 1-2
102 minutes) a vagal-mediated response associated with an increase of airway resistance assessed by
103 impedance plethysmography and end-tidal PCO₂ by capnometry. In addition, measures of airway
104 inflammation (indirect, fraction of exhaled nitric oxide), reactivity (direct, methacholine challenge),
105 and/or reversibility were also obtained. Therefore, these findings suggest focusing the attention on the
106 potential role of the parasympathetic system as a trigger of bronchial obstruction at least in a group of
107 asthmatics reporting the usual onset of cholinergic-related n-RSs (i.e. stress and/or anxiety) before an
108 asthma attack. We have hypothesized that, in some individuals, this condition of enhanced basal
109 cholinergic tone might play a predominant role in determining airway obstruction, compared with other
110 well-known factors such as allergens, air pollutants, infections, or exercise (a new “asthma
111 phenotype”?) (11).

112 The vagal hyperactivity induced by anxiety and stress in asthmatics also represents the basis of
113 important considerations by a therapeutic point of view, such as the use of anticholinergic agents
114 (12,13).

116 *Suggestions from “Asthma-Stress” and “AAIITO Regione Campania” Working Groups*

118 Since organizing bloody films vision could be of difficult feasibility in outpatient settings, the use of
119 placebo administration has the advantage of exploiting the patient's inherent fear of taking drugs and
120 the ambient situation that simulates taking an “active” drug thus inducing a stress status. A subject
121 suffering from asthma and anxiety/depression with a real or “presumed” history of drug-related adverse
122 reaction represents the ideal candidate. Indeed, it is not relevant to have a proven drug allergy but it is
123 essential that the patient is convinced to be “allergic” to drugs.

124 The suggested flow-chart to evaluate the possible role of “nocebo effect” in the induction of bronchial
125 obstruction in these asthmatics has been summarized in figure 1.

126 The occurrence of airways obstruction or the worsening of an already present obstruction as assessed
127 by spirometric evaluation, indicates a likely relationship between the parallel onset of stress and
128 bronchospasm. In case of development of an associated onset of other parasympathetic stress-related
129 symptoms (e.g. abdominal pain, reflux, dry mouth etc.), this could support our hypothesis of a possible
130 “asthma phenotype” characterized by a high systemic cholinergic tone.

131 According to our previous study (11), a simple question exploring the presence of vagal-related n-RSs
132 during the collection of anamnestic data could help identify asthmatics with an imbalance between
133 sympathetic and parasympathetic systems. These individuals could benefit of a further diagnostic
134 evaluation e.g. oxygen and methacholine inhalation, neck suction, slow deep breathing assessed by
135 multiple frequency forced oscillation technique (FOT), measurement of resting heart rate and
136 pupillometry of a possible higher basal cholinergic tone (14), laryngeal dysfunction questionnaire
137 (LDQ) (15) which might be elevated by a “nocebo effect” induced-psychological distress. Following
138 this hypothesis, our suggested procedure (figure 1) could be a useful method to assess if an induced
139 stress is able to start or increase airway obstruction in the single asthmatic patient. This demonstration
140 could have important diagnostic (e.g. for asthma phenotyping), preventive (e.g. for avoidance of
141 stressing situations) and therapeutic consequences such as the importance of psychological support in
142 these individuals. In addition, since the degree of cholinergic tone is likely to be different among
143 asthmatics, we believe it is not possible to rule out that the effectiveness of anticholinergic agents such
144 as tiotropium could be greater in patients with an increased degree of cholinergic tone (11-13). This

145 potential increased responsiveness to tiotropium may be usefully exploited also in the event of poor
146 treatment efficacy or occurrence of adverse events with the use of long-acting β_2 -adrenoceptor agonists
147 (LABAs) (16).
148

149 In conclusion, the currently available literature indicates that anxiety and related psychological
150 disorders should be considered as mechanisms that might trigger airway inflammation, the onset of
151 asthma attacks, and the severity of respiratory symptoms. We believe that our suggested diagnostic
152 procedure could be a useful model to assess the relationship between an induced stress/anxiety
153 condition and the onset or aggravating bronchial obstruction in asthmatics (with a real or “presumed”
154 ADR). Further studies should be planned to confirm our hypothesis in clinical practice.
155
156
157

158 **Acknowledgements**

159 We thank the biologist Dr. Paola Berra and miss Lucia Franzese for technical assistance in the
160 preparation of this manuscript.

161 162 **References**

- 163
164 1. Bizzi F, Voltolini S, Fiaschi MD, Cavanna D. Assessing clinical and psychological features:
165 who are patients showing a nocebo reaction during the drug challenge test? *Eur Ann Allergy Clin*
166 *Immunol* 2019; 51: 258-64
167
- 168 2. Liccardi G, Senna G, Russo M, Bonadonna F, Crivellaro M, Dama A, D’Amato M, D’Amato G,
169 Canonica GW, Passalacqua G. Evaluation of the nocebo effect during oral challenge in patients with
170 adverse drug reactions. *J Investig Allergol Clin Immunol* 2004; 14:104-107.
- 171 3. Lee JW, Tay TR, Paddle P, Richards AJ, Pointon L, Voortman M, Abramson MJ, Hoy R, Hew M.
172 Diagnosis of concomitant inducible laryngeal obstruction and asthma. *Clin Exp Allergy*. 2018;
173 48:1622-1630
- 174 4. Liccardi G, Baldi G, Berra A, Carpentieri E, Cutajar M, D’Amato M, Del Donno M, Del Prato B,
175 Folletti I, Gani F, Gargano L, Giannattasio D, Giovannini M, Infantino A, Lombardi C, Lo Schiavo M,
176 Madonna F, Maniscalco M, Meriggi A, Milanese M, Montera C, Pio A, Russo M, Salzillo A, Scavalli
177 P, Scichilone N, Sposato B, Stanziola A, Starace A, Vatrella A, D’Amato G, Passalacqua G. Non-
178 respiratory symptoms in asthma as possible predictors of exacerbations. *J Allergy Clin Immunol Pract*
179 2015;3 :798-800.
180
- 181 5. Heffner KL, Niccolt-Glaser JK, Glaser R, Malarkey WB, Marshall GD. Stress and anxiety
182 effects on positive skin test responses in young adults with allergic rhinitis. *Ann Allergy Asthma*
183 *Immunol* 2017; 113: 13-18
184
- 185 6. Li Y, Ho R, Lim TK, Kuan WS, Goh DY, Mahadevan M, Sim TB, Van Bever HP, Larbi A,
186 Ng TF. Neuropeptide Y may mediate psychological stress and enhance TH2 inflammatory
187 response in asthma. *J Allergy Clin Immunol* 2015; 135: 1061-63

- 188 7. Kawano T, Ouchi R, Ishigaki T, Masuda C, Miyasaka T, Ohkawara Y, Ohta N, Takayanagi M,
189 Takahashi T, Ohno I. Increased Susceptibility to Allergic Asthma with the Impairment of Respiratory
190 Tolerance Caused by Psychological Stress. *Int Arch Allergy Immunol.* 2018;177(1):1-15.
- 191 8. Ritz T, Kullowatz A, Goldman MD Smith HJ, Kannies F, Dahme B, Magnussen H. Airway
192 response to emotional stimuli in asthma: the role of the cholinergic pathway. *J Appl Physiol*
193 2010; 108: 1542-49
- 194 9. Janssens T, Steele AM, Rosenfield D, Ritz T. Airway reactivity in response to repeated emotional
195 film clip presentation in asthma. *Biol Psychol.* 2017 Feb;123:1-7.
- 196 10. Ritz T, Rosenfield D, Wilhelm FH Roth WT. Airway constriction in asthma during sustained
197 emotional stimulations with films. *Biol Psychol* 2012 ;91 : 8-16
- 198
- 199 11. Liccardi G, Salzillo A, Calzetta L, Cazzola M, Matera MG, Rogliani P. Can bronchial asthma with
200 a highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype?
201 Possible role of anticholinergics. *Respir Med* 2016; 117: 150-53
- 202
- 203 12. Liccardi G, Salzillo A, Calzetta L, Ora J, Cazzola M, Matera MG, Rogliani P. Can an increased
204 cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate
205 asthma? *J Allergy Clin Immunol Pract* 2016; 4: 791-93
- 206
- 207 13. Liccardi G, Calzetta L, Salzillo A, Piccolo A, Pano G, Rogliani P. Can a better patient phenotyping
208 predict the efficacy of tiotropium in asthmatic adolescents? *Expert Opin Pharmacother.* 2017; 18:833-
209 35.
- 210
- 211 14. Zannin E, Pellegrino R, Di Toro A, Antonelli A, Dellacà RL, Bernardi L. Parasympathetic stimuli
212 on bronchial and cardiovascular systems in humans. *PLoS One* 2015 ;10: e0127697.
- 213
- 214 15. Vertigan AE, Bone SL, Gibson PG. Development and validation of the Newcastle laryngeal
215 hypersensitivity questionnaire. *Cough* 2014; 10: 1.
- 216
- 217 16. Peters SP, Bleecker ER, Kuschner SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT,
218 Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Craig T, Denlinger LC, Engle LL,
219 Dimango EA, Israel E, Kraft M, Lazarus SC, Lemanske RF Jr, Lugogo N, Martin RJ, Meyers
220 DA, Ramsdell J, Sorkness CA, Sutherland ER, Wasserman SI, Walter MJ, Wechsler ME,
221 Chinchilli VM, Szeffler GJ. Predictors of response to tiotropium versus salmeterol in asthmatic
222 adults. *J Allergy Clin Immunol* 2013; 132: 1068-74.
- 223
- 224

225 Legends:

226

227 **Figure 1.** Suggested flow-chart to evaluate the possible role of “nocebo effect” in the induction of
228 bronchial obstruction in asthmatics suffering from anxiety/depression. FOT: forced oscillation
229 technique, LAMA: long-acting muscarinic antagonist; LDQ: laryngeal dysfunction questionnaire
230
231
232

233
234
235
236
237
238

Manuscript accepted for publication